Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,222 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, With Complications Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Approaches to Foot Complication Prevention: A Survey of Diabetes Educators

NCT04400344
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
No intervention
Other
Lead sponsor
Podimetrics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 2, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

Atrasentan Spermatogenesis and Testicular Function

NCT02118714
View directory record Official record
Conditions
Nephropathy, Diabetes
Interventions
Atrasentan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years to 75 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Laguna Hills, California • Santa Monica, California • Evergreen Park, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 2, 2026, 10:29 AM EDT
Completed Phase 4 Interventional Results available

Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery

NCT00596687
View directory record Official record
Conditions
Type 2 Diabetes, Inpatient Hyperglycemia
Interventions
Insulin glargine, Regular insulin, Insulin glulisine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 2, 2026, 10:29 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Safety and Efficacy of the Noxsano Wound Care Bandage

NCT04123093
View directory record Official record
Conditions
Wound Heal, Peripheral Artery Disease, Ulcer, Leg, Ulcer Foot, Diabetic Foot Ulcer, Arterial Insufficiency
Interventions
Noxsano Bandage (Healthy Volunteers), Noxsano Bandage (Wound Care)
Device
Lead sponsor
OhioHealth
Other
Eligibility
18 Years to 79 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 2, 2026, 10:29 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers

NCT00318214
View directory record Official record
Conditions
Foot Ulcer, Diabetic, Diabetes Complications
Interventions
MRE0094, Vehicle gel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 2, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

NCT06599684
View directory record Official record
Conditions
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema, Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Interventions
INV-102
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 2, 2026, 10:29 AM EDT
Completed Not applicable Interventional

SDRM® vs. Collagen for Diabetic Foot Ulcers

NCT05883098
View directory record Official record
Conditions
Diabetic Foot, Ulcer Foot, Wound Heal
Interventions
Wound debridement, Wound closure matrix application
Procedure · Device
Lead sponsor
Polymedics Innovations Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Circleville, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 2, 2026, 10:29 AM EDT
Not yet recruiting Phase 2 Interventional

Precision T1D Platform - New Therapies for Cardio-Renal Complications

NCT07594145
View directory record Official record
Conditions
Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
Interventions
Finerenone, Sotagliflozin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Ann Arbor, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 2, 2026, 10:29 AM EDT
Completed Phase 4 Interventional Results available

Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes

NCT02502071
View directory record Official record
Conditions
Type 1 Diabetes, Diabetic Nephropathy, Diabetic Kidney Disease
Interventions
sodium bicarbonate
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 2, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus (GDM)

NCT01158131
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Balance after Baby Lifestyle Intervention Program
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Oct 2, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Results available

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

NCT00090519
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
ruboxistaurin, placebo
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
36
States / cities
Artesia, California • Palm Springs, California • Poway, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 2, 2026, 10:29 AM EDT
Recruiting No phase listed Observational

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

NCT01802034
View directory record Official record
Conditions
Kidney Diseases, Kidney Failure, Chronic, Diabetic Nephropathy, Lupus Nephritis, Glomerulonephritis, IGA
Interventions
Not listed
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 2, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics

NCT06948292
View directory record Official record
Conditions
Chronic Kidney Disease Stages 3-5, Diabetic Kidney Disease, Hypertensive Kidney Disease
Interventions
QRX-3
Drug
Lead sponsor
Ebima Clifford Okundaye
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pasedena, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 2, 2026, 10:29 AM EDT
Active, not recruiting Phase 4 Interventional

A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

NCT04469595
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Iluvien 0.19 MG Drug Implant, Aflibercept
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 2, 2026, 10:29 AM EDT
Completed Not applicable Interventional Results available

Implementation of Telemedicine for Patient With Lower Extremity Wounds

NCT04440839
View directory record Official record
Conditions
Peripheral Arterial Disease, Peripheral Artery Disease, Peripheral Vascular Diseases, Diabetic Foot, Diabetic Foot Ulcer, Diabetic Foot Infection, Diabetic Peripheral Neuropathy
Interventions
Telemedicine specialty consultation
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 2, 2026, 10:29 AM EDT
Completed Not applicable Interventional Results available

Quantitative Assessment of Painful Diabetic Peripheral Neuropathy After High Frequency Spinal Cord Stimulation

NCT03769675
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
High Frequency Spinal Cord Stimulator
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 2, 2026, 10:29 AM EDT
Completed Phase 4 Interventional

A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)

NCT00168857
View directory record Official record
Conditions
Hypertension, Diabetic Nephropathies
Interventions
telmisartan, losartan
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
21 Years to 80 Years
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
47
States / cities
Montgomery, Alabama • Little Rock, Arkansas • Lancaster, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 2, 2026, 10:29 AM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

NCT04083339
View directory record Official record
Conditions
Diabetic Cardiomyopathies
Interventions
AT-001, Placebo
Drug
Lead sponsor
Applied Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
28
States / cities
Beverly Hills, California • La Jolla, California • Lincoln, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 2, 2026, 10:29 AM EDT
Recruiting Not applicable Interventional

Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers

NCT06681428
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers
Interventions
Allograft
Other
Lead sponsor
Tides Medical
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Fresno, California • Los Angeles, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 2, 2026, 10:29 AM EDT
Completed Phase 2 Interventional Results available

The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy

NCT02643251
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Neuropathy
Interventions
Clonidine Hydrochloride Topical Gel, 0.1%, Clonidine Hydrochloride Gel Comparator
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
25
States / cities
Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 2, 2026, 10:29 AM EDT
Recruiting Not applicable Interventional

CARE-D-FOOT-Nav Pilot

NCT07143175
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU)
Interventions
Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 2, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

NCT02017171
View directory record Official record
Conditions
Diabetic Nephropathies, Coronary Artery Disease
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Aurora, Colorado • Denver, Colorado • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 2, 2026, 10:29 AM EDT
Withdrawn Phase 2 Interventional

P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease

NCT06489340
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
2HPβCD
Drug
Lead sponsor
ZyVersa Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 2, 2026, 10:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

NCT02949024
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
IVT Aflibercept, SC CLS-TA
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Mountain View, California • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 2, 2026, 10:29 AM EDT